Skip to main content

Illumina Expands Line of Sequencers Further with Scaled-Down Version of Genome Analyzer

Premium

This story was originally published January 15, 2010.

Illumina last week launched the Genome Analyzer IIe, a smaller version of its cousin, the Genome Analyzer IIx.

The launch of the GAIIe comes two days after Illumina announced a new high-end sequencer, HiSeq 2000, that will provide up to 200 gigabases of data per run and up to 2 billion paired-end reads and has a list price of $690,000 (see In Sequence 1/12/2010).

With a list price of $250,000, the new GAIIe is "designed to provide a lower-priced entry point into next-generation sequencing," according to the company.

The system will start shipping this quarter.

Initially, the GAIIe will provide an output of up to 20 gigabases of data and approximately 200 million paired-end reads per run. With further improvements, the instrument’s output is expected to reach up to 40 gigabases and 300 million paired-end reads per run.

For comparison, the GAIIx • using a new reagent kit that Illumina said it would launch last week • delivers up to 50 gigabases of data and up to 500 million paired-end reads per run.

Illumina said the new instrument’s price and ease of use “ideally positions it for smaller laboratories interested in next-generation sequencing.”

In addition to the HiSeq 2000, GAIIx, and GAIIe, the company is also working on a sequencing module for its iScan system, called iScanSQ, which it plans to launch in the second quarter.

Besides Illumina, other vendors have also started offering different versions of their high-throughput sequencing platforms that are geared at different types of customers. Roche’s 454 Life Sciences, for example, last fall announced the Genome Sequencer Junior, a smaller and less expensive version of its GS FLX, that it plans to launch in the spring or early summer (see In Sequence 12/1/2009).

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.